Ocugen
0.97
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Ocugen
Ocugen公司是一家生物制药公司，致力于治疗眼病的疗法的开发和商业化。它的候选产品线包括OCU400、OCU410、OCU200和COVAXIN。该公司的修饰基因治疗平台致力于治疗视网膜疾病，包括视网膜色素变性、Leber先天性黑色素沉着症和干性老年性黄斑变性。该公司由Shankar Musunuri和Uday B.Kompella于2013年创立，总部设在宾夕法尼亚州马尔文。
Trade GPT
Similar Stocks
© 2025 Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.
Rockalpha Limited, operates from its Singapore headquarters at CapitaSky 808, 79 Robinson Road, Singapore 068897, with a regional office at Level 6, Core C, Cyberport 3, 100 Cyberport Road, Hong Kong.